Breaking News Instant updates and real-time market news.

ACAD

Acadia

$21.99

0.31 (1.43%)

16:11
11/06/18
11/06
16:11
11/06/18
16:11

Acadia reports Q3 EPS (50c), consensus (58c)

Reports Q3 revenue $58.3M, consensus $56.31M. At September 30, 2018, ACADIA's cash, cash equivalents and investment securities totaled $214.1M, compared to $341.3M at December 31, 2017.

  • 06

    Nov

  • 12

    Nov

ACAD Acadia
$21.99

0.31 (1.43%)

10/16/18
CANT
10/16/18
NO CHANGE
Target $27
CANT
Overweight
Acadia price target raised to $27 from $25 at Cantor Fitzgerald
Cantor Fitzgerald analyst Charles Duncan raised his price target for Acadia Pharmaceuticals to $27 and reiterates an Overweight rating on the shares. Acadia in August announced a licensing agreement with Neuren Pharmaceuticals for Trofinetide in Rett syndrome, Duncan tells investors in a research note. The analyst believes this is an underappreciated asset that could diversify the company's pipeline strategy over the next 12 months. After meeting with Neuren, Duncan has enhanced conviction on Trofinetide and believes that the path forward increases Phase 3 probability of success in the "as-yet untreatable neurodevelopmental disorder."
10/31/18
PIPR
10/31/18
NO CHANGE
PIPR
Overweight
Acadia depression data warrant 15% share upside, says Piper Jaffray
Acadia Pharmaceuticals this morning announced positive results with Nuplazid in major depressive disorder from its Phase 2 trial, Piper Jaffray analyst Danielle Brill tells investors in a research note titled "A Few Tricks, But Mostly Treats for ACAD Today: Data Overall De-Risk MDD Opportunity". Nuplazid demonstrated statistically significant improvements across multiple efficacy endpoints, says the analyst. She interprets the results as an "overall positive given an evident trend of benefit with Nuplazid." While the results aren't a clear "homerun," share upside of around 15% is warranted, Brill contends. She estimates such a move would reflect a 20%-30% risk adjusted major depressive disorder opportunity of $750M. Brill keeps an Overweight rating on Acadia with a $25 price target. The stock in morning trading is down 3%, or 68c, to $20.41.
11/01/18
CANT
11/01/18
NO CHANGE
Target $30
CANT
Overweight
Acadia price target raised to $30 from $27 at Cantor Fitzgerald
Cantor Fitzgerald analyst Charles Duncan raised his price target for Acadia Pharmaceuticals to $30 citing the positive top-line data from the non-zero risk Phase 2 Clarity study of pimavanserin in major depressive disorder. The analyst now believes we now believe pimavanserin use in MDD may prove to be a longer-term revenue driver, especially for high-burden patients and despite emerging/later-stage efforts with glutamate-modulating drugs. He reiterates an Overweight rating on Acadia.
11/01/18
HCWC
11/01/18
NO CHANGE
Target $60
HCWC
Buy
Acadia stage 1 results outweigh stage 2 miss, says H.C. Wainwright
H.C. Wainwright analyst Andrew Fein thinks Acadia Pharmaceuticals' top-line data release yesterday provided supportive evidence for pimavanserin's potential as an adjunctive therapy for major depressive disorder. However, he points out two major concerns from the study that he believes could shape this program's risks. Although the study hit primary endpoint of change in HAMD-17 score from baseline in stage 1 and in combined analysis, there was no significant benefit observed with pimavanserin treatment versus placebo in stage 2 of the study, Fein tells investors in a research note titled "Trick or Treat? Stage 1 Results Outweigh Stage 2 Miss, In Our View." This result naturally raises the question whether the treatment effect was indeed real rather than an artifact, says the analyst. And second, Fein points out that there has not been any drug approved by the FDA using a sequential parallel comparison design. This, he believes, would add to the regulatory risk of the program, given that the Phase 3 trial would be similar in design to the Clarity trial, per management. Fein has a Buy rating on Acadia with a $60 price target.

TODAY'S FREE FLY STORIES

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

14:17
02/20/19
02/20
14:17
02/20/19
14:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

14:16
02/20/19
02/20
14:16
02/20/19
14:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ETSY

Etsy

$54.65

-0.65 (-1.18%)

14:15
02/20/19
02/20
14:15
02/20/19
14:15
Options
Etsy put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Feb

  • 25

    Feb

  • 07

    Mar

  • 07

    Mar

SPX

S&P 500

$0.00

(0.00%)

, SPY

SPDR S&P 500 ETF Trust

$278.60

0.71 (0.26%)

14:09
02/20/19
02/20
14:09
02/20/19
14:09
General news
'Almost all' Fed members wanted to announce plan to stop reducing assets »

Minutes from the last…

SPX

S&P 500

$0.00

(0.00%)

SPY

SPDR S&P 500 ETF Trust

$278.60

0.71 (0.26%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPX

S&P 500

$0.00

(0.00%)

, SPY

SPDR S&P 500 ETF Trust

$278.27

0.38 (0.14%)

14:06
02/20/19
02/20
14:06
02/20/19
14:06
General news
Fed saw 'variety of considerations' for 'patient approach to monetary policy' »

Minutes from the last…

SPX

S&P 500

$0.00

(0.00%)

SPY

SPDR S&P 500 ETF Trust

$278.27

0.38 (0.14%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPX

S&P 500

$0.00

(0.00%)

, SPY

SPDR S&P 500 ETF Trust

$278.32

0.43 (0.15%)

14:05
02/20/19
02/20
14:05
02/20/19
14:05
General news
Fed to continue monitoring economic developments for outlook implications »

Minutes from the last…

SPX

S&P 500

$0.00

(0.00%)

SPY

SPDR S&P 500 ETF Trust

$278.32

0.43 (0.15%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPX

S&P 500

$0.00

(0.00%)

, SPY

SPDR S&P 500 ETF Trust

$278.34

0.45 (0.16%)

14:02
02/20/19
02/20
14:02
02/20/19
14:02
General news
Fed sees 'sustained expansion of economic activity' as most likely outcome »

Minutes from the last…

SPX

S&P 500

$0.00

(0.00%)

SPY

SPDR S&P 500 ETF Trust

$278.34

0.45 (0.16%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FDP

Fresh Del Monte

$29.97

0.7 (2.39%)

14:00
02/20/19
02/20
14:00
02/20/19
14:00
Hot Stocks
Breaking Hot Stocks news story on Fresh Del Monte »

Fresh Del Monte trading…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BHC

Bausch Health

$23.13

-2.04 (-8.10%)

14:00
02/20/19
02/20
14:00
02/20/19
14:00
Options
Dip buyer in Bausch Health Companies »

Dip buyer in Bausch…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

  • 20

    Feb

  • 25

    Feb

  • 25

    Feb

  • 25

    Feb

  • 12

    Mar

  • 12

    Mar

VLKAY

Volkswagen

$0.00

(0.00%)

, AUDVF

Audi AG

$0.00

(0.00%)

13:59
02/20/19
02/20
13:59
02/20/19
13:59
Periodicals
Audi plans to cut 10% of management positions, Reuters reports »

Audi (AUDVF),…

VLKAY

Volkswagen

$0.00

(0.00%)

AUDVF

Audi AG

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TTD

Trade Desk

$146.31

-15.45 (-9.55%)

13:58
02/20/19
02/20
13:58
02/20/19
13:58
On The Fly
Trade Desk slides after analyst cuts rating ahead of quarterly results »

Shares of Trade Desk…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

  • 21

    Feb

  • 06

    Mar

  • 06

    Mar

UA

Under Armour

$19.15

-0.23 (-1.19%)

13:55
02/20/19
02/20
13:55
02/20/19
13:55
Options
Under Armour put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Mar

  • 06

    Mar

PM

Philip Morris

$85.42

2 (2.40%)

13:50
02/20/19
02/20
13:50
02/20/19
13:50
Earnings
Philip Morris repeats Q1 reported diluted EPS view of $1.00, consensus $1.01 »

As communicated on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PM

Philip Morris

$85.42

2 (2.40%)

13:49
02/20/19
02/20
13:49
02/20/19
13:49
Earnings
Philip Morris reaffirms FY19 reported diluted EPS guidance of at least $5.37 »

Philip Morris…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

13:45
02/20/19
02/20
13:45
02/20/19
13:45
General news
Fed's Kaplan said a weaker business outlook is the reason for caution on rates »

Fed's Kaplan said a…

13:45
02/20/19
02/20
13:45
02/20/19
13:45
General news
Breaking General news story  »

FOMC Minutes to be…

MDR

McDermott

$7.80

0.44 (5.98%)

13:40
02/20/19
02/20
13:40
02/20/19
13:40
Options
Bullish option play in McDermott as shares rally ahead of earnings »

Bullish option play in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Feb

  • 25

    Feb

  • 04

    Mar

  • 05

    Mar

  • 12

    Mar

  • 17

    Mar

  • 18

    Mar

  • 02

    May

STAG

STAG Industrial

$28.24

-0.59 (-2.05%)

13:34
02/20/19
02/20
13:34
02/20/19
13:34
Recommendations
STAG Industrial analyst commentary  »

STAG Industrial price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GOOG

Alphabet

$1,118.00

-0.16 (-0.01%)

, GOOGL

Alphabet Class A

$1,125.12

-1.31 (-0.12%)

13:28
02/20/19
02/20
13:28
02/20/19
13:28
Periodicals
Epic Games stops 'Fortnite' pre-roll ads on YouTube due to predators, Verge says »

Epic Games is no longer…

GOOG

Alphabet

$1,118.00

-0.16 (-0.01%)

GOOGL

Alphabet Class A

$1,125.12

-1.31 (-0.12%)

TCEHY

Tencent

$0.00

(0.00%)

DIS

Disney

$113.63

0.11 (0.10%)

KKR

KKR

$23.52

-0.2 (-0.84%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Feb

  • 25

    Feb

  • 27

    Feb

  • 03

    Mar

  • 07

    Mar

  • 18

    Mar

SPX

S&P 500

$0.00

(0.00%)

, SPY

SPDR S&P 500 ETF Trust

$278.00

0.11 (0.04%)

13:28
02/20/19
02/20
13:28
02/20/19
13:28
Periodicals
Barr could announce end of Mueller investigation next week, CNN reports »

Attorney General Bill…

SPX

S&P 500

$0.00

(0.00%)

SPY

SPDR S&P 500 ETF Trust

$278.00

0.11 (0.04%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

OMI

Owens & Minor

$6.40

-1.54 (-19.40%)

13:24
02/20/19
02/20
13:24
02/20/19
13:24
Periodicals
Owens & Minor working with banks to explore sale, Reuters reports »

Owens & Minor is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

OMI

Owens & Minor

$6.41

-1.53 (-19.27%)

13:20
02/20/19
02/20
13:20
02/20/19
13:20
Hot Stocks
Breaking Hot Stocks news story on Owens & Minor »

Owens & Minor trading…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

OMI

Owens & Minor

$6.41

-1.53 (-19.27%)

13:18
02/20/19
02/20
13:18
02/20/19
13:18
Hot Stocks
Breaking Hot Stocks news story on Owens & Minor »

Owens & Minor halted…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

GOLD

Barrick Gold

$13.98

0.43 (3.17%)

13:17
02/20/19
02/20
13:17
02/20/19
13:17
Hot Stocks
Barrick Gold confirms commitment to Chile as it reviews LATAM strategy »

The company said,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

OMI

Owens & Minor

$6.41

-1.53 (-19.27%)

13:17
02/20/19
02/20
13:17
02/20/19
13:17
Periodicals
Breaking Periodicals news story on Owens & Minor »

Owens & Minor…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.